A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This study is to determine the appropriate dosing regimen of GS-9820 in subjects with
lymphoid malignancies. This is a Phase 1b, open-label, dose-escalation and expansion study
evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of GS-9820.